Multi-dimensional target profiling of N,4-diaryl-1,3-thiazole-2-amines as potent inhibitors of eicosanoid metabolism

European Journal of Medicinal Chemistry

Volumn 84, Issue , 2014, Pages 302-311

  Rödl, Carmen B ^a   Vogt, Dominik ^a   Kretschmer, Simon B M ^a   Ihlefeld, Katja ^a   Barzen, Sebastian ^a   Brüggerhoff, Astrid ^a   Achenbach, Janosch ^a   Proschak, Ewgenij ^a   Steinhilber, Dieter ^a   Stark, Holger ^a,b   Hofmann, Bettina ^a  

^a GOETHE UNIVERSITY   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

5 Lipoxygenase; Cancer; Cardiovascular diseases; Cyclooxygenase; Inflammation; Thiazole 2 amines

Indexed keywords

2 (4 PHENYL)THIAZOL 2 YLAMINO)PHENOL; 2 [4 (4 CHLOROPHENYL)THIAZOL 2 YLAMINO]PHENOL; ALPHA PENTYL 3 (2 QUINOLYLMETHOXY)BENZYL ALCOHOL; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ICOSANOID; LIPOXYGENASE INHIBITOR; N 4 DIARYL 1,3 THIAZOLE 2 AMINE DERIVATIVE; PROSTAGLANDIN SYNTHASE INHIBITOR; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; ZILEUTON; CYCLOOXYGENASE 2 INHIBITOR; 2-(4-(4-CHLOROPHENYL)THIAZOL-2-YLAMINO)PHENOL; 2-(4-PHENYL)THIAZOL-2-YLAMINO)PHENOL; AMINOPHENOL DERIVATIVE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; ENZYME INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL MEMBRANE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; IC 50; ICOSANOID METABOLISM; MICROWAVE IRRADIATION; STRUCTURE ACTIVITY RELATION; DRUG SELECTIVITY; DRUG TARGETING; IC50; SUBSTITUTION REACTION; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; HELA CELL LINE; METABOLISM; SYNTHESIS; TUMOR CELL CULTURE; U937 CELL LINE;

5-LIPOXYGENASE-ACTIVATING PROTEINS; AMINOPHENOLS; CYCLOOXYGENASE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; EICOSANOIDS; ENZYME INHIBITORS; HELA CELLS; HUMANS; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; TUMOR CELLS, CULTURED; U937 CELLS;

EID: 84904554172     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.07.025     Document Type: Article

References (69)

1. M. Peters-Golden, and W.R. Henderson Leukotrienes N. Engl. J. Med. 357 2007 1841 1854
2. O. Werz, and D. Steinhilber Therapeutic options for 5-lipoxygenase inhibitors Pharmacol. Ther. 112 2006 701 718 (Pubitemid 44592614)
3. S.E. Dahlén, P. Hedqvist, S. Hammarström, and B. Samuelsson Leukotrienes are potent constrictors of human bronchi Nature 288 1980 484 486 (Pubitemid 11163960)
4. M. Korotkova, and P.-J. Jakobsson Persisting eicosanoid pathways in rheumatic diseases Nat. Rev. Rheumatol. 10 2014 229 241
5. B. Samuelsson, S.E. Dahlén, J.A. Lindgren, C.A. Rouzer, and C.N. Serhan Leukotrienes and lipoxins: structures, biosynthesis, and biological effects Science 237 1987 1171 1176 (Pubitemid 17131222)
6. D.K. Miller, J.W. Gillard, P.J. Vickers, S. Sadowski, C. Léveillé, and J.A. Mancini et al. Identification and isolation of a membrane protein necessary for leukotriene production Nature 343 1990 278 281
7. J.W. Woods, J.F. Evans, D. Ethier, S. Scott, P.J. Vickers, and L. Hearn et al. 5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes J. Exp. Med. 178 1993 1935 1946 (Pubitemid 23344852)
8. O. Rådmark, O. Werz, D. Steinhilber, and B. Samuelsson 5-Lipoxygenase: regulation of expression and enzyme activity Trends Biochem. Sci. 32 2007 332 341 (Pubitemid 47021417)
9. A.W. Ford-Hutchinson, M.A. Bray, M.V. Doig, M.E. Shipley, and M.J. Smith Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes Nature 286 1980 264 265 (Pubitemid 10009985)
10. P. Correa Human gastric carcinogenesis: a multistep and multifactorial process - First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention Cancer Res. 52 1992 6735 6740 (Pubitemid 23006271)
11. K. Kawai, M. Yamamoto, S. Kameyama, H. Kawamata, A. Rademaker, and R. Oyasu Enhancement of rat urinary bladder tumorigenesis by lipopolysaccharide- induced inflammation Cancer Res. 53 1993 5172 5175 (Pubitemid 23333383)
12. S.I. Grivennikov, F.R. Greten, and M. Karin Immunity, inflammation, and cancer Cell. 140 2010 883 899
13. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell. 144 2011 646 674
14. Y.Q. Chen, Z.M. Duniec, B. Liu, W. Hagmann, X. Gao, and K. Shimoji et al. Endogenous 12(S)-HETE production by tumor cells and its role in metastasis Cancer Res. 54 1994 1574 1579 (Pubitemid 24106425)
15. X.-Z. Ding, R. Hennig, and T.E. Adrian Lipoxygenase and cyclooxygenase metabolism: new insights in treatment and chemoprevention of pancreatic cancer Mol. Cancer 2 2003 10
16. D. Nie, M. Che, D. Grignon, K. Tang, and K.V. Honn Role of eicosanoids in prostate cancer progression Cancer Metastasis Rev. 20 2001 195 206 (Pubitemid 34595268)
17. J.B. Nixon, K.S. Kim, P.W. Lamb, F.G. Bottone, and T.E. Eling 15-Lipoxygenase-1 has anti-tumorigenic effects in colorectal cancer Prostagl. Leukot. Essent. Fat. Acids 70 2004 7 15 (Pubitemid 38021636)
18. R.M. Garavito Prostaglandin Endoperoxide H synthases (Cyclooxygenases)-1 and -2 J. Biol. Chem. 271 1996 33157 33160 (Pubitemid 27010118)
19. L.J. Marnett, S.W. Rowlinson, D.C. Goodwin, A.S. Kalgutkar, and C.A. Lanzo Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition J. Biol. Chem. 274 1999 22903 22906
20. T. Hla, D. Bishop-Bailey, C.H. Liu, H.J. Schaefers, and O.C. Trifan Cyclooxygenase-1 and -2 isoenzymes Int. J. Biochem. Cell. Biol. 31 1999 551 557 (Pubitemid 29219401)
21. S. Hara, A. Miyata, C. Yokoyama, H. Inoue, R. Brugger, and F. Lottspeich et al. Isolation and molecular cloning of prostacyclin synthase from bovine endothelial cells J. Biol. Chem. 269 1994 19897 19903 (Pubitemid 24250905)
22. S. Narumiya Prostanoids in immunity: roles revealed by mice deficient in their receptors Life Sci. 74 2003 391 395 (Pubitemid 37357068)
23. T. Okuno, Y. Iizuka, H. Okazaki, T. Yokomizo, R. Taguchi, and T. Shimizu 12(S)-Hydroxyheptadeca-5Z, 8E, 10E-trienoic acid is a natural ligand for leukotriene B4 receptor 2 J. Exp. Med. 205 2008 759 766 (Pubitemid 351549875)
24. K. Brune, and B. Hinz The discovery and development of antiinflammatory drugs Arthritis Rheum. 50 2004 2391 2399 (Pubitemid 39066262)
25. C.J. Hawkey Cyclooxygenase inhibition: between the devil and the deep blue sea Gut 50 Suppl. 3 2002 III25 30
26. J.L. Masferrer, B.S. Zweifel, P.T. Manning, S.D. Hauser, K.M. Leahy, and W.G. Smith et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic Proc. Natl. Acad. Sci. USA 91 1994 3228 3232 (Pubitemid 24130209)
27. L.J. Marnett The COXIB experience: a look in the rearview mirror Annu. Rev. Pharmacol. Toxicol. 49 2009 265 290
28. E.W. Ehrich, A. Dallob, I. De Lepeleire, A. Van Hecken, D. Riendeau, and W. Yuan et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model Clin. Pharmacol. Ther. 65 1999 336 347 (Pubitemid 29142940)
29. J.-M. Dogné, C.T. Supuran, and D. Pratico Adverse cardiovascular effects of the coxibs J. Med. Chem. 48 2005 2251 2257 (Pubitemid 40516417)
30. D.H. Solomon Selective cyclooxygenase 2 inhibitors and cardiovascular events Arthritis Rheum. 52 2005 1968 1978 (Pubitemid 40994317)
31. B.F. McAdam, F. Catella-Lawson, I.A. Mardini, S. Kapoor, J.A. Lawson, and G.A. FitzGerald Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2 Proc. Natl. Acad. Sci. USA. 96 1999 272 277 (Pubitemid 29036089)
32. I. Melnikova Pain market Nat. Rev. Drug. Discov. 9 2010 589 590
33. C. He, Y. Wu, Y. Lai, Z. Cai, Y. Liu, and L. Lai Dynamic eicosanoid responses upon different inhibitor and combination treatments on the arachidonic acid metabolic network Mol. Biosyst. 8 2012 1585 1594
34. A.J. Duffield-Lillico, J.O. Boyle, X.K. Zhou, A. Ghosh, G.S. Butala, and K. Subbaramaiah et al. Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway Cancer Prev. Res. (Phila) 2 2009 322 329
35. M. Romano, and J. Claria Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy FASEB J. 17 2003 1986 1995 (Pubitemid 37392443)
36. X.Z. Ding, W.G. Tong, and T.E. Adrian Cyclooxygenases and lipoxygenases as potential targets for treatment of pancreatic cancer Pancreatology 1 2001 291 299 (Pubitemid 33758405)
37. H. Stark Turning from monogamy to strategic promiscuity Drug. Discov. Today 9 2004 736 737 (Pubitemid 39140799)
38. E. Proschak Reconsidering the drug discovery pipeline for designed multitarget drugs Drug. Discov. Today 18 2013 1129 1130
39. S.H. Hwang, A.T. Wecksler, K. Wagner, and B.D. Hammock Rationally designed multitarget agents against inflammation and pain Curr. Med. Chem. 20 2013 1783 1799
40. K. Meirer, D. Steinhilber, and E. Proschak Inhibitors of the arachidonic acid cascade: interfering with multiple pathways Basic Clin. Pharmacol. Toxicol. 114 2014 83 91
41. B. Hofmann, and D. Steinhilber 5-Lipoxygenase inhibitors: a review of recent patents (2010-2012) Expert Opin. Ther. Pat. 23 2013 895 909
42. K. Yang, W. Ma, H. Liang, Q. Ouyang, C. Tang, and L. Lai Dynamic simulations on the arachidonic acid metabolic network PLoS Comput. Biol. 3 2007 e55
43. K. Fogh, T. Herlin, and K. Kragballe In vitro inhibition of leukotriene B4 formation by exogeneous 5-lipoxygenase inhibitors is associated with enhanced generation of 15-hydroxy-eicosatetraenoic acid (15-HETE) by human neutrophils Arch. Dermatol. Res. 280 1988 430 436
44. R. Morphy, and Z. Rankovic Designing multiple ligands - medicinal chemistry strategies and challenges Curr. Pharm. Des. 15 2009 587 600
45. B. Smith, H.-H. Chang, F. Medda, V. Gokhale, J. Dietrich, and A. Davis et al. Synthesis and biological activity of 2-aminothiazoles as novel inhibitors of PGE2 production in cells Bioorg. Med. Chem. Lett. 22 2012 3567 3570
46. J. Suh, E.K. Yum, H.G. Cheon, and Y.S. Cho Synthesis and biological evaluation of N-aryl-4-aryl-1,3-thiazole-2-amine derivatives as direct 5-lipoxygenase inhibitors Chem. Biol. Drug. Des. 80 2012 89 98
47. W.J. Hantzsch, and A. Über Verbindungen des Thiazols (Pyridins der Thiophenreihe) Ber. Dtsch. Chem. Ges. 20 2 1887 118 3132
48. C.R. Rasmussen, F.J. Villani Jr., L.E. Weaner, B.E. Reynolds, A.R. Hood, L.R. Hecker, S.O. Nortey, A. Hanslin, M.J. Costanzo, E.T. Powell, and A.J. Molinari Improved procedures for the preparation of Cycloalkyl-, Arylalkyl-, and arylthioureas Synth. (Stuttg.) 6 1988 456 459
49. A.S. Fischer, J. Metzner, S.D. Steinbrink, S. Ulrich, C. Angioni, and G. Geisslinger et al. 5-Lipoxygenase inhibitors induce potent anti-proliferative and cytotoxic effects in human tumour cells independently of suppression of 5-lipoxygenase activity Br. J. Pharmacol. 161 2010 936 949
50. S. Fiorucci, R. Meli, M. Bucci, and G. Cirino Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? Biochem. Pharmacol. 62 2001 1433 1438 (Pubitemid 33145286)
51. J. Martel-Pelletier, D. Lajeunesse, P. Reboul, and J.-P. Pelletier Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs Ann. Rheum. Dis. 62 2003 501 509 (Pubitemid 36606279)
52. X. Ding, C. Zhu, H. Qiang, X. Zhou, and G. Zhou Enhancing antitumor effects in pancreatic cancer cells by combined use of COX-2 and 5-LOX inhibitors Biomed. Pharmacother. 65 2011 486 490
53. M.N. Muscará, N. Vergnolle, F. Lovren, C.R. Triggle, S.N. Elliott, and S. Asfaha et al. Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence Br. J. Pharmacol. 129 2000 1423 1430 (Pubitemid 30175715)
54. L. Parente Pros and cons of selective inhibition of cyclooxygenase-2 versus dual lipoxygenase/cyclooxygenase inhibition: is two better than one? J. Rheumatol. 28 2001 2375 2382 (Pubitemid 33031963)
55. A.D. Michelson Antiplatelet therapies for the treatment of cardiovascular disease Nat. Rev. Drug. Discov. 9 2010 154 169
56. D. Albert, I. Zündorf, T. Dingermann, W.E. Müller, D. Steinhilber, and O. Werz Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase Biochem. Pharmacol. 64 2002 1767 1775 (Pubitemid 35355728)
57. J. Lötsch, and G. Geisslinger Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effects Drug. Discov. Today 16 2011 1001 1006
58. K.J. French, R.S. Schrecengost, B.D. Lee, Y. Zhuang, S.N. Smith, and J.L. Eberly et al. Discovery and evaluation of inhibitors of human sphingosine kinase Cancer Res. 63 2003 5962 5969 (Pubitemid 37187498)
59. G.T. Kunkel, M. Maceyka, S. Milstien, and S. Spiegel Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond Nat. Rev. Drug. Discov. 12 2013 688 702
60. C. Loveridge, F. Tonelli, T. Leclercq, K.G. Lim, J.S. Long, and E. Berdyshev et al. The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p- chlorophenyl)thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells J. Biol. Chem. 285 2010 38841 38852
61. S. Ren, C. Xin, J. Pfeilschifter, and A. Huwiler A novel mode of action of the putative sphingosine kinase inhibitor 2-(p-hydroxyanilino)-4-(p- chlorophenyl) thiazole (SKI II): induction of lysosomal sphingosine kinase 1 degradation Cell. Physiol. Biochem. 26 2010 97 104
62. N. Siddiqui, and W. Ahsan Triazole incorporated thiazoles as a new class of anticonvulsants: design, synthesis and in vivo screening Eur. J. Med. Chem. 45 2010 1536 1543
63. O. Werz Activation of 5-lipoxygenase by cell stress is calcium independent in human polymorphonuclear leukocytes Blood 99 2002 1044 1052 (Pubitemid 34527142)
64. C.B. Rödl, Y. Tanrikulu, J.M. Wisniewska, E. Proschak, G. Schneider, and D. Steinhilber et al. Potent inhibitors of 5-lipoxygenase identified using pseudoreceptors ChemMedChem. 6 2011 1001 1005
65. M. Brungs, O. Rådmark, B. Samuelsson, and D. Steinhilber Sequential induction of 5-lipoxygenase gene expression and activity in Mono Mac 6 cells by transforming growth factor beta and 1,25-dihydroxyvitamin D3 Proc. Natl. Acad. Sci. USA 92 1995 107 111
66. T. Hammarberg, Y.Y. Zhang, B. Lind, O. Radmark, and B. Samuelsson Mutations at the C-terminal isoleucine and other potential iron ligands of 5-lipoxygenase Eur. J. Biochem. 230 1995 401 407
67. T. Hammarberg, P. Provost, B. Persson, and O. Rådmark The N-terminal domain of 5-lipoxygenase binds calcium and mediates calcium stimulation of enzyme activity J. Biol. Chem. 275 2000 38787 38793 (Pubitemid 32009215)
68. A.-K. Häfner, M. Cernescu, B. Hofmann, M. Ermisch, M. Hörnig, and J. Metzner et al. Dimerization of human 5-lipoxygenase Biol. Chem. 392 2011 1097 1111
69. C. Ritz, and J. Streibig Bioassay analysis using R J. Stat. Softw. 12 2005 1 22 (Pubitemid 40218001)